|
|
|
|
| LEADER |
01842nam a2200265 u 4500 |
| 001 |
EB002001749 |
| 003 |
EBX01000000000000001164650 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Clinical review report: Tapentadol hydrochloride extended-release tablet (Nucynta extended-release)
|h Elektronische Ressource
|b (Paladin labs inc.)
|
| 246 |
3 |
1 |
|a Clinical Review Report for Nucynta extended-release
|
| 246 |
3 |
1 |
|a Tapentadol hydrochloride extended-release tablet (Nucynta extended-release)
|
| 250 |
|
|
|a Final
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2018, October 2018
|
| 300 |
|
|
|a 1 PDF file (161 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "Indication: Management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate. Tapentadol extended-release tablet is not indicated as an as-needed (prn) analgesic."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK540241
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The objective of this review is to perform a systematic review of the beneficial and harmful effects of tapentadol hydrochloride extended-release tablets (Nucynta Extended-Release) 100 mg to 250 mg twice a day for the management of pain severe enough to require daily, continuous, long-term opioid treatment, and: that is opioid responsive; and for which alternative treatment options are inadequate. Nucynta Extended-Release is not indicated as an as-needed analgesic
|